Asset profile
Alemtuzumab
Monoclonal antibody
Approvedregulatory verdict
Evidence outlook
Approved: Multiple Sclerosis
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Partial signal
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
44 competitors in this universe: 0 direct rivals (same mechanism and indication), 0 same-class, 44 same-indication.
Unlock with Research ↗
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Alemtuzumab: this drug | Approved | Monoclonal antibody | CD52 | ||
| Aldesleukin (Proleukin) | Approved | Recombinant Cytokine (il-2) | Interleukin-2 receptor (IL-2R) | ||
| Bafiertam | Approved | Small molecule | Nrf2 pathway (fumaric acid ester) | ||
| Cladribine (MAVENCLAD®) | Approved | Small molecule | Adenosine deaminase-resistant purine analog, DNA synthesis machinery in lymphocytes | ||
| Copaxone | Approved | Peptide | Myelin basic protein-mimetic immunomodulation | ||
| Dimethyl Fumarate (Tecfidera) | Approved | Small molecule | Nrf2 pathway (fumaric acid ester) | ||
| Diroximel Fumarate (Vumerity) | Approved | Small molecule | Nrf2 pathway (fumaric acid ester) | ||
| DRF | Approved | Small molecule | Nrf2 pathway (fumaric acid ester) | ||
| Fampridine (Ampyra / Fampyra) | Approved | Small molecule | Potassium Channel Blocker, Voltage-gated potassium channel (Kv), Voltage-gated potassium channels (Kv1/Shaker/KCNA family) | ||
| Fingolimod (Gilenya) | Approved | Small molecule | Sphingosine 1-phosphate receptor (S1PR, specifically S1P1), S1P receptor, Sphingosine-1-phosphate receptors (S1P1, S1P3, S1P4, S1P5) | ||
| Interferon Beta-1a (Avonex) | Approved | Biologic (subtype unspecified) | Type I Interferon receptor (IFNAR) | ||
| Interferon Beta-1b | Approved | Biologic (subtype unspecified) | Interferon beta receptor (type I IFN signaling), Type I interferon receptor | ||
| Interferon-Beta1 | Approved | Biologic (subtype unspecified) | Type I interferon receptor | ||
| Mayzent | Approved | Small molecule | S1P receptor | ||
| Natalizumab (Tysabri) | Approved | Monoclonal antibody | α4 integrin | ||
| Ocrelizumab | Approved | Monoclonal antibody | CD20 |
…and 29 more. Research shows the complete landscape.
Research
Unlock with Research ↗Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Upcoming events
(26 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2026 (6)
November 2026 (2)
Phase 2Primary Immunodeficiency (PID), Congenital Bone Marrow Failure Syndromes, Inherited Metabolic Disorders (IMD), Hereditary Anemias …Recruiting
Est. primary completion 2026-11 · NCT01962415 · CT.gov ↗
What to watch
Phase 2Sickle Cell DiseaseActive not recruiting
Est. primary completion 2026-11 · NCT04018937 · CT.gov ↗
What to watch
December 2026 (4)
Phase 1/2Crohn's DiseaseRecruiting
Est. primary completion 2026-12 · NCT00692939 · CT.gov ↗
What to watch
Phase 1/2Metabolic Disorders, Hematologic, Immune, or Bone Marrow Disorders, Hemoglobinopathies, Non-malignant DisordersRecruiting
Est. primary completion 2026-12 · NCT00920972 · CT.gov ↗
What to watch
Phase 2Dyskeratosis Congenita, Hoyeraal Hreidarsson Syndrome, Revesz Syndrome, Aplastic AnemiaActive not recruiting
Est. primary completion 2026-12 · NCT01659606 · CT.gov ↗
What to watch
Phase 1Sickle Cell DiseaseActive not recruiting
Est. primary completion 2026-12-01 · NCT05384756 · CT.gov ↗
What to watch
2027 (6)
January 2027 (1)
Phase 2Fanconi Anemia, Severe Aplastic Anemia, Myelodysplastic Syndromes, T Cell Receptor Alpha/Beta Depletion, Telomere Biology Disorder …Recruiting
Est. primary completion 2027-01-01 · NCT03579875 · CT.gov ↗
What to watch
October 2027 (1)
Phase 1/2CD40L-HyperIgM SyndromeRecruiting
Est. primary completion 2027-10-28 · NCT06959771 · CT.gov ↗
What to watch
December 2027 (4)
Phase 1/2Idiopathic Pulmonary Fibrosis, Emphysema or COPDRecruiting
Est. primary completion 2027-12 · NCT03500731 · CT.gov ↗
What to watch
Phase 1/2Chronic Granulomatous Disease TransplantActive not recruiting
Est. primary completion 2027-12-30 · NCT02629120 · CT.gov ↗
What to watch
Phase 2Primary Immune Deficiency Disorder, Immune Deficiency Disease, Bone Marrow Failure, Short Telomere Length, Fanconi Anemia …Recruiting
Est. primary completion 2027-12-31 · NCT04232085 · CT.gov ↗
What to watch
Phase 2Secondary Malignant Neoplasm of Retroperitoneum, Secondary Malignant Neoplasm of Peritoneum, Pseudomyxoma PeritoneiNot yet recruiting
Est. primary completion 2027-12-31 · NCT06084780 · CT.gov ↗
What to watch
2028 (5)
July 2028 (1)
Phase 2Sickle Cell Disease, Stem Cell Transplant Complications, Red Blood Cell Disorder, Pure Red Cell AplasiaRecruiting
Est. primary completion 2028-07 · NCT03214354 · CT.gov ↗
What to watch
August 2028 (3)
Phase 1/2Sickle Cell Anemia, Beta-thalassemia Major, Diamond-blackfan AnemiaRecruiting
Est. primary completion 2028-08-01 · NCT03653338 · CT.gov ↗
What to watch
Phase 2Systemic Sclerosis, Diffuse Sclerosis Systemic, Interstitial Lung Disease, Pulmonary HypertensionRecruiting
Est. primary completion 2028-08-01 · NCT03630211 · CT.gov ↗
What to watch
Phase 2Allogeneic Hematopoietic Cell TransplantationRecruiting
Est. primary completion 2028-08-31 · NCT05501756 · CT.gov ↗
What to watch
September 2028 (1)
Phase 1/2Sickle Cell DiseaseActive not recruiting
Est. primary completion 2028-09-23 · NCT01499888 · CT.gov ↗
What to watch
2030 (3)
March 2030 (1)
Phase 1Sickling Disorder Due to Hemoglobin SRecruiting
Est. primary completion 2030-03-12 · NCT07015684 · CT.gov ↗
What to watch
June 2030 (1)
Phase 2Graft Failure, Sickle Cell Disease, HemoglobinopathiesRecruiting
Est. primary completion 2030-06-01 · NCT06872333 · CT.gov ↗
What to watch
November 2030 (1)
Phase 2Sickle Cell DiseaseRecruiting
Est. primary completion 2030-11 · NCT03587272 · CT.gov ↗
What to watch
2032 (3)
June 2032 (1)
Phase 1/2Sickle Cell Disease, Beta-thalassemiaRecruiting
Est. primary completion 2032-06-30 · NCT07599176 · CT.gov ↗
What to watch
December 2032 (2)
2034 (2)
2044 (1)
September 2044 (1)
Phase 2Sickle Cell DiseaseRecruiting
Est. primary completion 2044-09 · NCT06358638 · CT.gov ↗
What to watch
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.